WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs

SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs),  today announced the signing of a Memorandum of Understanding (MOU) with AbTis, a leading ADC biotechnology company based in South Korea. This partnership brings together AbTis' proprietary site-selective conjugation platform AbClick® and WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. The collaboration aims to accelerate ADC therapeutic innovation by integrating AbTis' cutting-edge technology into WuXi XDC's toolbox, while fostering new opportunities for global clients.

Through this agreement, WuXi XDC will incorporate AbTis' advanced site-selective conjugation technologies including the AbClick® Platform, which utilizes affinity peptide-assisted linkers to enable precise and efficient antibody-drug conjugation. Additionally, WuXi XDC will facilitate potential collaborations between AbTis and its extensive client network, expanding the global reach of AbTis Technologies while unlocking synergistic market opportunities. This collaboration highlights a shared commitment to advancing innovation and delivering state-of-the-art solutions to the bioconjugate drug industry. By enhancing CMC platform capabilities, both companies aim to empower clients to accelerate preclinical candidate selection, develop next-generation ADCs, and expedite CMC development timelines.

Dr. Jimmy Li, CEO of WuXi XDC, commented, "This collaboration with AbTis underscores our commitment to advancing innovation through strategic partnerships and creating meaningful value for our clients. With the addition of AbTis' innovative conjugation technology into the WuXi XDC technology suite, it will provide our clients with broader options of advanced bioconjugation technologies and will tailormade solutions to support the advancement of next-generation ADCs and bioconjugate drugs."

Dr. Tae Dong Han, CEO of AbTis, commented, "This partnership with WuXi XDC marks a significant milestone for AbTis as we expand the reach of our site-selective conjugation technology. By leveraging WuXi XDC's extensive global network and integrated CRDMO platforms alongside AbTis' innovative bioconjugation technologies and comprehensive expertise, we aim to create a synergy that amplifies the accessibility and impact of our innovations. Together, we are well-positioned to drive and support the development of groundbreaking ADC therapeutics, delivering meaningful benefits to patients worldwide."

About WuXi XDC

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: wuxixdc.com

Contacts

Investor Inquiry: wuxixdc.ir@wuxibiologics.com
Media Inquiry: wuxixdc_pr@wuxibiologics.com
Business Development: wuxixdc_info@wuxibiologics.com

About AbTis

AbTis is a pioneering biotechnology company transforming the development of bioconjugate therapies through its proprietary AbClick® platform technology. AbTis' innovative technologies enable site-selective conjugation through a streamlined and cost-efficient process, empowering the development of diverse bioconjugate therapeutics -including ADCs, DACs, AOCs, ISACs, and ARCs- without any need for antibody modification. AbTis provides precise control over critical parameters such as half-life, drug-to-antibody ratio (DAR), and linker-payload stability - essential elements for designing optimal bioconjugate therapy.

With unwavering commitment to improving the quality of life for patients worldwide, AbTis is dedicated to advancing innovative pipelines with global partners, delivering positive economic impact and long-term value. For more information about AbTis, please visit: www.abtis.co.kr

Contacts

Investor and Media Inquiry: abtis@donga.co.kr
Business Development: mkkim@donga.co.kr